Cellular and T cell engager Immunotherapy
Phase I study to evaluate cellular immunotherapy using CS-1 targeting autologous CAR T cells in patients with relapsed and refractory multiple myeloma (RRMM)
Myo Htut, MD
Associate Professor, Department of Hematology & Hematopoietic Cell Transplantation
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Pts | LDC | CAR T cell dose (million) | Best Response | DLT |
340 | Flu (30 mg/m2) + Cy (500 mg/m2) | 100 | PR | Grade 5 HLH |
443 | Flu (30mg/m2) + Cy (500 mg/m2) | 10 | PR | Grade 3 HLH |
524 | None | 10 | PD | |
542 | None | 10 | SD | |
568 | None | 50 | PD | |
619 | None | 50 | PD | |
638 | Cy (300 mg/m2) | 10 | PD | |
674 | Cy (300 mg/m2) | 10 | SD | |
next cohort | Reduced dose Flu (25 mg/m2) + Cy (300 mg/m2) | 10 |